Covera Health, the country’s leading provider of clinical analytics solutions to reduce medical misdiagnoses and improve healthcare quality, announced the integration of ScreenPoint Medical’s artificial intelligence (AI) tools into its quality analytics platform. Covera plans to leverage these tools to improve early detection of breast cancer for both patients and providers, which has been proven to drive more effective –– and often less invasive –– treatment, improving outcomes for women nationwide.
“We’re proud to announce this new program enhancement during Breast Cancer Awareness Month, and even prouder that we’re able to make such a positive contribution to the health of women nationwide,” said Ron Vianu, Covera Health co-founder and CEO.
Covera plans to announce additional improvements to the program with other third-party tools in the near future. “Integrating robust third-party applications, AI or otherwise, within the Covera Health ecosystem is an exciting step for us. The platform we’ve built connecting providers and payers allows for these quality-improving tools to reach millions of patients, virtually overnight,” explained Vianu further.
Richard Herzog, MD, FACR, Covera’s Chief Medical Officer noted that “We’re excited to be able to deliver continued value to our physician partners across the country, which has the potential to save millions of lives through earlier detection of breast cancers.”
ScreenPoint Medical’s FDA-approved Transpara® tool is the world’s first dedicated AI decision support solution for 2D and 3D mammography. It not only helps radiologists detect cancers earlier for better treatment and improved survival rates, but also reduces the rate of false positives as well.
One in every eight women will develop breast cancer in her lifetime, according to the National Breast Cancer Foundation, and more than 42,000 women in the United States will die of breast cancer this year. It is now the most common cancer among women worldwide. When breast cancer is detected early and is in the localized stage, the five-year survival rate is 99 percent, according to the American Cancer Society. Annual mammograms remain a critical tool for early detection.
About Covera Health
Covera Health, a leading clinical analytics company, connects providers with employers and health plans – and their millions of patients – over its quality platform. Its analytics and quality insights reduce the prevalence and impact of medical misdiagnosis, a leading cause of patient harm, inappropriate care, and unnecessary cost. Its first product, the Radiology Center of Excellence program, is available in 50 states. For more information, visit www.coverahealth.com.
About ScreenPoint Medical
ScreenPoint Medical is the leading developer of AI-driven image analysis technology which enables the automated reading of mammograms and digital breast tomosynthesis examinations. With proven accuracy at least matching that of experienced radiologists, ScreenPoint’s Transpara™ system is the most advanced available, exploiting big data, deep learning and the latest advances in artificial intelligence. The system can identify high-risk breast lesions quickly, enabling earlier detection, earlier treatment and a greater chance of survival. For more information, visit https://screenpoint-medical.com/.